GENENTECH: FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders
Rituxan in combination with glucocorticoids is the only FDA-approved therapy for adults with these two rare forms of vasculitis